Director of Commercial Medicines Negotiation at NHS England. Also tweets on rugby, running, Chesterfield FC. Tweets in a personal capacity. RT ≠ endorsement etc
What an amazing show from @youarestars (and Murray A. Lightburn from @thedears) last night: still sounding just as powerful as the first time I saw them 18 years ago. And we get to do it all again tonight! Please, please play “Going, Going, Gone” to make my weekend complete…
Thank you @MHPHealth and @petedigger for hosting an excellent roundtable this morning: a great opportunity to discuss how pharma and the NHS can work together to make innovative, good value medicines available to patients.
Delighted to have hosted our Life Sciences Industry Roundtable this morning where we were joined by @robkettell and colleagues from NHS England's Commercial Medicines Directorate. It was a lively, insightful and engaging discussion - thank you to all that attended 🧬🔬
Delighted that NHS England’s Commercial Medicines Directorate and @NICEComms have worked successfully with @MSDintheUK to secure access to this important new breast cancer treatment: highlighting our ongoing work to make good value, innovative treatments available to patients.
Lauren is fully recovered from triple-negative breast cancer thanks to a trial of a new treatment which will now be rolled out on the NHS.
This could save lives of more people like Lauren, who has been able to run races, continue her career in the NHS and be with her loved ones.
Thank you @WA_Comms for hosting an excellent roundtable: a great opportunity to discuss how NHS England and pharma companies can continue to work together to achieve rapid patient access to innovative medicines.
Earlier this month, WA's Head of Health @cal_gordon held a roundtable discussion with @robkettell, Director of Commercial Medicines Negotiation and Complex Transactions at NHS England. Here, we outline the five key takeaways from the discussion: https://t.co/5wpTPujuXH
Today, @NHSEngland in partnership with @NICEComms, launch the Innovative Medicines Fund - the Fund will continue NHS momentum as an adopter of medical innovation through agreements that also safeguard value for taxpayers. https://t.co/cOs67nKXt9
Hundreds of people with the most common form of an aggressive lung cancer could survive twice as long, thanks to a drug now available on the NHS.
The drug, durvalumab, can double the overall time someone can survive from two and a half to five years. 👉 https://t.co/kYoIwSYjk8
WHAT A BEAUTIFUL TRY!! 😍
Excellent work from Danny Care to keep it in, then Marcus Smith sets off like a rocket! Playing in Cadan Murley who plays in Joe Marchant for the try! 🔥
Sensational rugby from @Harlequins! 💫
#HeinekenChampionsCup
This is a dispatch for history. About a mass grave of children. One killed on the soccer field. Another so young that an umbilical cord is still attached. By the last two international journalists in Mariupol, risking their lives to write. @ap https://t.co/T9eKWb6t2U
A revolutionary tumour-stopping drug for lung cancer will be made available to anyone who is eligible, thanks to a new deal announced today.
Read how hundreds more patients will now be able to receive this first-of-its-kind treatment. ➡️ https://t.co/BH1X5foNF2
‘The NHS continues to focus on finding ways to push the boundaries of what we can do to help provide earlier diagnosis for patients and better outcomes.’
NHS Chief Executive @AmandaPritchard visited @UHD_NHS to see their cutting-edge treatment for cancer. #WorldCancerDay
I want to thank the dedicated, talented and inspirational group of people that I had the privilege to work with over the last 3 years: I have learnt so much from all of you about how primary care makes such a positive difference to so many people’s lives. 3/3
@PrimaryCareNHS
Some personal news: after nearly 3 years leading work on Primary Care Networks and the GP Contract for NHS England, I’m excited to be taking up a new role today as Director of Commercial Negotiation and Complex Transactions in the NHS England Commercial Medicines Directorate. 1/3
I’m looking forward to working with Blake Dark and his team, supporting patient access to healthcare innovations with the greatest benefits to patients and with the best value propositions for the NHS and taxpayers. 2/3